Table 2. Tumor-free survival and tumor spectrum in p53^−/− mice with secondary CIN-inducing mutations.

Median tumor-free survival is shown as the median survival of the double mutant cohort versus the p53^−/− cohort, respectively. Studies in which effect on tumor phenotype is listed as unchanged are those in which the difference in survival between p53^−/− and doubly mutant mice was not statistically significant.

Secondary Mutation	Median Tumor Free Survival (days)	Primary Tumor Type	Effect on Tumor Phenotype	Reference
Bub1^{+/H ^}	~175 vs ~175	thymic lymphoma	Unchanged	(Li et al., 2010)
Bub1^+/−	~175 vs ~175	thymic lymphoma	Unchanged
Bub1^H/H	~90 vs ~175	thymic lymphoma	Exacerbated
Bub1^−/H	~85 vs ~175	thymic lymphoma	Exacerbated
Cdc20^+/AAA	~120 vs ~210	thymic lymphoma	Exacerbated
Separase^+/H	118 vs 151	lymphoma	Exacerbated	(Mukherjee et al., 2011)
Mps1^f/+;p53^f/f; Lck-Cre (T cells)^&	~140 vs 150 in p53^f/f;Lck-Cre	T-cell acute lymphoblastic lymphoma	Unchanged	(Foijer et al., 2014)
Mps1^f/f p53^f/f; Lck-Cre (T cells)	~105 vs ~150 in p53^f/f;Lck-Cre	T-cell acute lymphoblastic lymphoma	Exacerbated
Mps1^f/f p53^f/f; MMTV-Cre (mammary, T cells)	~100 vs ~200 in p53^f/f:MMTV-Cre	T-cell acute lymphoblastic lymphoma (no mammary)	Exacerbated
Plk4OE; p53^f/f; ERT-Cre (β-actin promoter)	~ 180 vs ~180 in p53^f/f;ERT-Cre	thymic lymphoma	Unchanged	(Vitre et al., 2015)
Plk4OE p53^f/f K14-Cre (epidermis)	175 vs 266 in p53^f/f ;K14-Cre^*	skin carcinoma	Exacerbated	(Sercin et al., 2016)
Plk4^OE/OEp53^−/− (ROSA26 locus)	105 vs 140	sarcoma	Exacerbated	(Coelho et al., 2015)

^{^}

H indicates hypomorphic allele

f indicates a floxed allele

average time to tumor onset

Table 2. Tumor-free survival and tumor spectrum in p53−/− mice with secondary CIN-inducing mutations.

Table 2. Tumor-free survival and tumor spectrum in p53^−/− mice with secondary CIN-inducing mutations.